CD274 and cancer: fabricated NPs composed of 4 agents to target cancer in multiple ways: paclitaxel, repertaxin (a cancer stem cell antagonist), BMS-1 (a PD-1/PD-L1 pathway blocker), and combretastatin A4 (targets tumor micro vessels).